1346604-93-0

Basic information

• Product Name: JWH 018 N-(3-methylbutyl) isomer
• Synonyms: JWH 018 N-(3-methylbutyl) isomer;[1-(3-methylbutyl)indol-3-yl]-naphthalen-1-ylmethanone
• CAS NO: 1346604-93-0
• Molecular Formula: C24H23NO
• Molecular Weight: 341.44552
• Mol File: 1346604-93-0.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: JWH 018 N-(3-methylbutyl) isomer(CAS DataBase Reference)
• NIST Chemistry Reference: JWH 018 N-(3-methylbutyl) isomer(1346604-93-0)
• EPA Substance Registry System: JWH 018 N-(3-methylbutyl) isomer(1346604-93-0)

Safety Data

• Hazardous Substances Data: 1346604-93-0(Hazardous Substances Data)

Usage

Description

JWH 018 N-(3-methylbutyl) isomer, also known as the 3-methylbutyl homolog of JWH 073 (B693550), is an analgesic compound that exhibits its effects by acting as a partial agonist at both the CB1 and CB2 cannabinoid receptors. This property allows it to provide pain relief and potentially other therapeutic benefits through interaction with the endocannabinoid system.

Uses

Used in Pharmaceutical Industry:
JWH 018 N-(3-methylbutyl) isomer is used as an analgesic agent for its ability to alleviate pain by acting as a partial agonist at the CB1 and CB2 cannabinoid receptors. This makes it a potential candidate for the development of new pain management therapies and medications.
Used in Pain Management:
JWH 018 N-(3-methylbutyl) isomer is used as a pain relief compound for its effectiveness in providing analgesia through interaction with the CB1 and CB2 cannabinoid receptors. This application can be beneficial in various medical conditions where pain relief is a primary concern, such as chronic pain, post-operative pain, and neuropathic pain.
Used in Research and Development:
JWH 018 N-(3-methylbutyl) isomer is used as a research compound for studying the endocannabinoid system and its role in various physiological processes, including pain perception, inflammation, and mood regulation. This can lead to a better understanding of the system and the development of novel therapeutic strategies targeting the CB1 and CB2 receptors.